Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has disclosed Current Deferred Revenue for 5 consecutive years, with $600000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Current Deferred Revenue rose 50.0% to $600000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $600000.0, a 50.0% increase, with the full-year FY2022 number at $900000.0, down 71.88% from a year prior.
  • Current Deferred Revenue was $600000.0 for Q3 2023 at Fulcrum Therapeutics, up from $513000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.9 million in Q4 2020 to a low of $1500.0 in Q3 2021.
  • A 5-year average of $4.0 million and a median of $1.5 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 99.99% in 2021, then skyrocketed 26566.67% in 2022.
  • Fulcrum Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then surged by 273.78% to $14.9 million in 2020, then tumbled by 78.54% to $3.2 million in 2021, then crashed by 71.88% to $900000.0 in 2022, then crashed by 33.33% to $600000.0 in 2023.
  • Per Business Quant, the three most recent readings for FULC's Current Deferred Revenue are $600000.0 (Q3 2023), $513000.0 (Q2 2023), and $737000.0 (Q1 2023).